Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 43 clinical trials
Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study

Hodgkin Lymphoma (HL) patients treated with brentuximab vedotin (BV)-containing regimens.

  • 0 views
  • 24 Jan, 2021
  • 21 locations
BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant

A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin's Lymphoma, Followed by

  • 0 views
  • 27 Jan, 2021
  • 19 locations
Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma

therapy by Brentuximab Vedotin (BV) for up to one year. The primary objective of the trial is to show efficacy of the experimental consolidative treatment strategy. Secondary objectives are to

  • 0 views
  • 26 Jan, 2021
  • 1 location
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs

rituximab
b-cell lymphoma
avid
brentuximab
measurable disease
  • 0 views
  • 05 May, 2021
  • 37 locations
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

This phase III trial compares immunotherapy drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV classic

gilbert's syndrome
pegfilgrastim
topical steroids
lymphoma
doxorubicin
  • 68 views
  • 05 May, 2021
  • 494 locations
Brentuximab Vedotin for Systemic Sclerosis

There is significant unmet need for effective treatment options for Diffuse Cutaneous Systemic Sclerosis (dcSSc). The present study will be a dose-escalation safety trial of brentuximab vedotin

raynaud's phenomenon
immunosuppressive agents
methotrexate
azathioprine
diffuse cutaneous systemic sclerosis
  • 710 views
  • 18 Apr, 2021
  • 10 locations
Brentuximab for Newly Diagnosed Hodgkin Disease

The addition of Brentuximab vedotin (Bv) to combination chemotherapy will be safe, well tolerated and effective in children, adolescents and young adults with all stages of newly diagnosed

lymphoma
chemotherapy regimen
brentuximab
doxorubicin
ejection fraction
  • 19 views
  • 24 Jan, 2021
  • 1 location
Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas

The trial assess the maximum tolerated dose of a single-dose of Brentuximab Vedotin added to standard BeEAM chemotherapy (comprising Bendamustin, Etoposide, Cyclophosphamide and Melphalan

platelet count
melphalan
t-cell lymphoma
etoposide
high dose chemotherapy
  • 4 views
  • 26 Jan, 2021
  • 1 location
Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis

The purpose of this study is to assess feasibility, safety and preliminary efficacy of Brentuximab vedotin (Adcetris), a CD30-directed antibody-drug conjugate, in the treatment of active diffuse

  • 63 views
  • 22 Apr, 2021
  • 1 location
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

anticancer drug (brentuximab vedotin) and three chemotherapy drugs (doxorubicin, vinblastine, and dacarbazine). These four drugs are called "A+AVD." Participants will be treated with granulocyte colony

colony stimulating factor
lymphoma
white blood cell count
doxorubicin
dacarbazine
  • 44 views
  • 05 May, 2021
  • 51 locations